Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature

Nivolumab is a programmed cell death receptor (PD-1) inhibitor that is increasingly used for various malignancies, both as a first line agent and as salvage therapy. Being a PD-1/PD-1 ligand checkpoint inhibitor, it is known to cause autoimmune inflammation of various organs and has been associated...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMJ Case Rep
Huvudupphovsmän: Abdullah, Hafez Mohammad Ammar, Elnair, Radowan, Khan, Uzma Ikhtiar, Omar, Muhammad, Morey-Vargas, Oscar L
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2019
Ämnen:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6721076/
https://ncbi.nlm.nih.gov/pubmed/31451458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-229568
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk